#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14730	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2117	691.3	0	.	n	.	0	G1015A	SNP	1015	1015	G	1291	1291	A	843	A,G,T	402,402,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14730	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2117	691.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1726	1726	T	782	T,C	722,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14730	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2117	691.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1460	1460	C	849	C	815	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27002	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	771.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1639	1639	A	894	A	854	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27002	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	771.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2273	2273	C	871	C,T	812,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27002	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	771.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2347	2347	A	847	A	803	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27002	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	771.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2899	2899	C	803	C,T,G	768,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2138	folP	855	855	100.0	folP.l15.c4.ctg.1	1546	137.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1005	1007	AGC	203;202;202	A;G;C	193;192;191	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5270	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3410	154.1	1	SNP	p	S91F	1	.	.	271	273	TTC	617	619	TTC	173;173;171	T;T;C,T	163;164;159,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5270	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3410	154.1	1	SNP	p	D95G	1	.	.	283	285	GGC	629	631	GGC	167;167;166	G;G,T;C	161;159,1;162	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5270	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3410	154.1	1	SNP	p	G95N	0	.	.	283	285	GGC	629	631	GGC	167;167;166	G;G,T;C	161;159,1;162	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1686	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1378	122.3	1	SNP	p	G45D	0	.	.	133	135	GGC	507	509	GGC	196;198;201	G;G;C	187;187;191	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	836	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	986	84.3	0	.	n	.	0	A197.	DEL	197	197	A	526	526	A	199	A	192	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4878	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3067	158.5	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1515	1517	GTC	193;193;193	G;T;C	183;185;183	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4878	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3067	158.5	1	SNP	p	D86N	0	.	.	256	258	GAC	621	623	GAC	200;200;200	G;A;C	179;177;181	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4878	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3067	158.5	1	SNP	p	S87R	1	.	.	259	261	CGT	624	626	CGT	199;202;205	C;G;T	184;183;187	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4878	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3067	158.5	1	SNP	p	R87W	0	.	.	259	261	CGT	624	626	CGT	199;202;205	C;G;T	184;183;187	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4878	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3067	158.5	1	SNP	p	R87I	0	.	.	259	261	CGT	624	626	CGT	199;202;205	C;G;T	184;183;187	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4878	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3067	158.5	1	SNP	p	S88P	0	.	.	262	264	TCC	627	629	TCC	204;204;203	T;C;C	186;189;189	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4348	parE	1986	1986	99.95	parE.l15.c17.ctg.1	2696	160.7	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1375	1377	TGC	202;203;203	T;G;C	190;194;193	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4348	parE	1986	1986	99.95	parE.l15.c17.ctg.1	2696	160.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1585	1587	GGC	225;225;223	G;G;C	214;213;211	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1251	1253	GCA	239;239;237	G;C;A	215;219;220	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1254	1256	ATC	235;237;240	A;T,C;C	216;220,1;220	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1266	1268	GTG	245;243;244	G;T;G	224;220;224	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1266	1268	GTG	245;243;244	G;T;G	224;220;224	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1770	1772	ACC	212;215;217	A;C;C	190;200;200	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1824	1826	GCG	205;205;201	G;C;G	179;172;164	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1824	1826	GCG	205;205;201	G;C;G	179;172;164	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1947	1949	GGC	176;174;177	G,T;G;C	161,1;156;162	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1956	1958	GGC	185;187;185	G;G;C	167;166;169	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4252	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2369	178.5	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1974	1976	TCG	184;187;186	T,G;C;G	115,8;143;150	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6110	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3116	195.3	0	.	p	.	0	E418G	NONSYN	1252	1254	GAG	1719	1721	GGG	220;218;216	G;G;G	188;192;192	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6110	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3116	195.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1728	1730	CCG	215;215;214	C;C;G,C	185;194;187,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2186	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1672	129.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	513	513	C	164	C	151	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	103	105	TTA	56;56;56	T;T;A	48;48;48	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	148	150	CAT	74;73;71	C;A;T	67;65;66	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	151	153	AGT	71;72;72	A;G;T	65;65;65	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	160	162	TAC	71;71;71	T;A;C	64;64;65	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	R307A	NONSYN	919	921	AGA	250	252	GCA	16;17;16	G;C;A	16;16;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	G308S	NONSYN	922	924	GGC	253	255	AGC	16;16;16	A;G;C	16;16;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	262	264	GCA	17;17;18	G;C;A	16;16;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	265	267	GAC	18;19;19	G;A;C	17;17;18	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	271	273	ATC	19;19;18	A;T;C	19;18;17	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	277	279	TCG	17;16;16	T;C;G	14;16;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	283	285	GCC	16;16;16	G;C;C	14;14;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	286	288	AGC	16;15;15	A;G;C	15;14;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	289	291	GCC	15;15;15	G;C;C	14;14;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	370	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	438	32.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	295	297	GTT	16;16;16	G;T;T	13;14;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	449	451	GAA	259;259;262	G;A;A	249;249;252	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	737	739	GAT	240;240;240	G;A;T	232;229;226	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	860	862	TCA	244;244;245	T;C,A;A	233;232,1;237	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1319	1321	GCA	223;221;222	G;C;A	206;205;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	0	.	p	.	0	G329S	NONSYN	985	987	GGC	1322	1324	AGC	224;228;228	A;G;C	207;210;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	1	SNP	p	G120K	1	.	.	358	360	AAG	695	697	AAG	219;221;224	A;A;G	214;214;213	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	1	SNP	p	A121D	1	.	.	361	363	GAC	698	700	GAC	222;222;223	G;A;C	211;208;212	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1527	197.5	1	SNP	p	D121N	0	.	.	361	363	GAC	698	700	GAC	222;222;223	G;A;C	211;208;212	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11078	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4830	228.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1941	1943	AAT	214;215;217	A;A;T	205;205;205	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1272	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	907	138.2	1	SNP	p	V57M	1	.	.	169	171	ATG	462	464	ATG	262;262;262	A;T;G	255;257;255	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
